ANABAnaptysBio, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~34% a year FCF growth. The price demands less than its three-year revenue growth of 164% a year, expectations look modest.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ANAB's price assumes
AnaptysBio, Inc. trades at 8.01× earnings against 18.8× for the median Biotechnology name, cheaper than its own group.
Trailing P/E · Biotechnology median 18.8 · cheaper than the typical name in its group
- Price / sales
- 7.21
Price / sales · as of 2026-Q2
- Free cash flow yield
- 0.60%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +34%
Growth the price implies · The price pays for +34% free cash flow growth a year for a decade; revenue has grown +164% a year over the last three.
Details›
- Price / bookas of 2026-Q2
- 162
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Free cash flow, trailing twelve months
- $10M
- Market capitalisation
- $1.74B
- 3-year revenue growth
- +164%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.